Wells Fargo’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.12M | Buy |
115,563
+22,359
| +24% | +$360K | ﹤0.01% | 3557 |
|
|
2026
Q1 | $1.82M | Sell |
93,204
-54,112
| -37% | -$1.61M | ﹤0.01% | 3342 |
|
|
2025
Q4 | $4.58M | Buy |
147,316
+41,436
| +39% | +$1.14M | ﹤0.01% | 2773 |
|
|
2025
Q3 | $2.28M | Buy |
105,880
+26,099
| +33% | +$471K | ﹤0.01% | 3221 |
|
|
2025
Q2 | $1.12M | Buy |
79,781
+3,448
| +5% | +$46.8K | ﹤0.01% | 3620 |
|
|
2025
Q1 | $1.03M | Buy |
76,333
+11,886
| +18% | +$202K | ﹤0.01% | 3636 |
|
|
2024
Q4 | $1.24M | Buy |
64,447
+15,443
| +32% | +$336K | ﹤0.01% | 3551 |
|
|
2024
Q3 | $1.11M | Buy |
49,004
+11,546
| +31% | +$189K | ﹤0.01% | 3482 |
|
|
2024
Q2 | $487K | Buy |
37,458
+5,330
| +17% | +$73.8K | ﹤0.01% | 3928 |
|
|
2024
Q1 | $563K | Buy |
32,128
+6,235
| +24% | +$121K | ﹤0.01% | 3813 |
|
|
2023
Q4 | $564K | Sell |
25,893
-46,536
| -64% | -$735K | ﹤0.01% | 3783 |
|
|
2023
Q3 | $1.11M | Buy |
72,429
+3,542
| +5% | +$67.6K | ﹤0.01% | 3258 |
|
|
2023
Q2 | $1.64M | Buy |
68,887
+22,929
| +50% | +$588K | ﹤0.01% | 3070 |
|
|
2023
Q1 | $1.17M | Buy |
+45,958
| New | +$1.47M | ﹤0.01% | 3268 |
|
|
2022
Q4 | – | Sell |
-808
| Closed | -$16K | – | 7759 |
|
|
2022
Q3 | $16K | Buy |
808
+194
| +32% | +$3.49K | ﹤0.01% | 5510 |
|
|
2022
Q2 | $7K | Buy |
614
+303
| +97% | +$4.07K | ﹤0.01% | 5913 |
|
|
2022
Q1 | $5K | Sell |
311
-175
| -36% | -$3.36K | ﹤0.01% | 6487 |
|
|
2021
Q4 | $9K | Buy |
486
+74
| +18% | +$1.38K | ﹤0.01% | 6592 |
|
|
2021
Q3 | $7K | Sell |
412
-107
| -21% | -$1.57K | ﹤0.01% | 6308 |
|
|
2021
Q2 | $10K | Buy |
519
+29
| +6% | +$496 | ﹤0.01% | 6151 |
|
|
2021
Q1 | $8K | Buy |
490
+2
| +0.4% | +$37 | ﹤0.01% | 6406 |
|
|
2020
Q4 | $8K | Sell |
488
-105
| -18% | -$1.58K | ﹤0.01% | 6071 |
|
|
2020
Q3 | $7K | Buy |
593
+576
| +3,388% | +$8.59K | ﹤0.01% | 5966 |
|
|
2020
Q2 | $0 | Hold |
17
| – | – | ﹤0.01% | 6889 |
|
|
2020
Q1 | $0 | Buy |
+17
| New | +$198 | ﹤0.01% | 6868 |
|
|
2019
Q3 | – | Sell |
-86
| Closed | -$3K | – | 6762 |
|
|
2019
Q2 | $3K | Sell |
86
-2,499
| -97% | -$100K | ﹤0.01% | 6126 |
|
|
2019
Q1 | $109K | Buy |
2,585
+288
| +13% | +$13K | ﹤0.01% | 5100 |
|
|
2018
Q4 | $105K | Buy |
2,297
+629
| +38% | +$36.4K | ﹤0.01% | 5259 |
|
|
2018
Q3 | $139K | Buy |
1,668
+81
| +5% | +$7.64K | ﹤0.01% | 5199 |
|
|
2018
Q2 | $153K | Buy |
1,587
+340
| +27% | +$35.9K | ﹤0.01% | 5166 |
|
|
2018
Q1 | $131K | Buy |
1,247
+60
| +5% | +$6.52K | ﹤0.01% | 5187 |
|
|
2017
Q4 | $185K | Buy |
1,187
+796
| +204% | +$101K | ﹤0.01% | 4997 |
|
|
2017
Q3 | $54K | Buy |
+391
| New | +$65.8K | ﹤0.01% | 5444 |
|
Other funds holding VRDN
BG
PBA
KCM
FFM
DTC
Wells Fargo's VRDN Position: Q2 2026 in Review
Wells Fargo increased its Viridian Therapeutics (VRDN) stake by 24% in Q2 2026, buying an estimated $360K and bringing the position to 115,563 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3557.
Wells Fargo first reported a position in VRDN in Q3 2017 and has held it in 33 quarters since. The position peaked at $4.58M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.
- Wells Fargo held 115,563 shares of Viridian Therapeutics worth $2.12M as of Q2 2026.
- Wells Fargo bought 22,359 Viridian Therapeutics shares in Q2 2026, an estimated $360K.
- Viridian Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3557 holding.
- Wells Fargo first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 33 quarters since.
- Wells Fargo's Viridian Therapeutics position peaked at $4.58M in Q4 2025.
- 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.